QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

Home・Akciju saraksts・Pharming Group NV

P
Pharming Group NV

Slēgts

1.453 -2.02

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.451

Max

1.458

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9M 7.5M
Pārdošana	4.1M 97M
EPS	0.006
Peļņas marža	7.758
Darbinieki	404

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	379M 997M
Iepriekšējā atvēršanas cena	3.47
Iepriekšējā slēgšanas cena	1.453

Pharming Group NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. nov. 17:45 UTC

Peļņas

Galvenie tirgus virzītāji

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

2025. g. 14. nov. 17:31 UTC

Peļņas

Galvenie tirgus virzītāji

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

2025. g. 15. nov. 18:03 UTC

Peļņas

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

2025. g. 15. nov. 15:43 UTC

Peļņas

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

2025. g. 15. nov. 12:00 UTC

Peļņas

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

2025. g. 15. nov. 09:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 15. nov. 09:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 15. nov. 00:08 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

2025. g. 14. nov. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

2025. g. 14. nov. 23:02 UTC

Tirgus saruna

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

2025. g. 14. nov. 22:35 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

2025. g. 14. nov. 22:32 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

2025. g. 14. nov. 22:29 UTC

Peļņas

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

2025. g. 14. nov. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

2025. g. 14. nov. 21:50 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 14. nov. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

2025. g. 14. nov. 20:27 UTC

Tirgus saruna

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

2025. g. 14. nov. 20:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

2025. g. 14. nov. 20:17 UTC

Iegādes, apvienošanās, pārņemšana

Several State Attorneys General Oppose Railroad Merger -- WSJ

2025. g. 14. nov. 19:29 UTC

Tirgus saruna

Peļņas

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

2025. g. 14. nov. 18:44 UTC

Tirgus saruna

Peļņas

Disney's Growth Now Hinges More on ESPN -- Market Talk

2025. g. 14. nov. 18:27 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 14. nov. 18:27 UTC

Tirgus saruna

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

2025. g. 14. nov. 18:20 UTC

Tirgus saruna

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

2025. g. 14. nov. 17:20 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 14. nov. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 14. nov. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 14. nov. 16:51 UTC

Tirgus saruna

Starbucks Gets Holiday Sales Lift -- Market Talk

2025. g. 14. nov. 16:48 UTC

Tirgus saruna

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

2025. g. 14. nov. 16:38 UTC

Tirgus saruna

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pharming Group NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pharming Group NV — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.